Insider trade

Director exercised or converted 1,500 REGN derivative securities

Traded Jan 7, 2026 · Filed Jan 8, 2026

Regeneron PharmaceuticalsREGN

1,500
Derivative units

Why it stands out

Derivative exercise or conversion — not an open-market buy.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: Jan 7, 2026
Reporting period: Not applicable
Filed with the SEC: Jan 8, 2026

DirectorOption exercise

Context

Classification

option exercise

Code M — exercise or conversion of a derivative security

Planned / mechanical clue

Footnote references a pre-arranged trading plan (Rule 10b5-1)

Only flagged when a footnote says so; never inferred

Source receipt

Record ID: 0001683607-26-000008

Filed / recorded

Jan 8, 2026, 9:03 PM UTC

Added to OQRO

Oct 2, 2026, 12:28 PM UTC

Parser

form4-xml-v1

Data quality

Verified: identifiers matched exactly

Issuer

REGENERON PHARMACEUTICALS, INC.

Issuer CIK

872589

Ticker

REGN

Reporting person

Bonnie L Bassler

Relationship

Director

Security

Non-Qualified Stock Option (right to buy)

Table

Derivative (Table II)

Transaction date

Jan 7, 2026

Transaction code

M

Shares / units

1,500

Price per share

$0.00

Acquired / disposed

Disposed (D)

Shares owned after

2,861

Ownership form

Direct

Amendment

No

Footnotes from the filing

Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 2, 2025.
On the date of the Company's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that had passed from the date of grant became exercisable, and the remainder became exercisable on the first anniversary of the date of grant.